

## Abstract sheet for the 2008 DFCON

**Submitting Author:** Jeffrey C. Karr DPM  
5421 South Florida Ave  
Lakeland, FL 33813  
863-646-5960 Office  
863-644-2847 fax

**Abstract title:** A review of utilizing living bi-layered cell therapy in lower extremity ulcerations following arterial vascular intervention.\*

**Abstract:** Among several commercially available bioengineered tissue grafts, there is only one bi-layered cell therapy\* that is approved by the FDA for the use with standard therapeutic compression in the treatment of non-infected partial- and full-thickness venous stasis ulcers as well as full thickness neuropathic diabetic foot ulcers. The bi-layered cell therapy expresses multiple growth factors found in normal skin, and provides a biologically active matrix. This presentation looks at the possibility of this bi-layered cell therapy\* being beneficial in the management of lower extremity ulcerations following arterial vascular intervention. The bi-layered cell therapy\* was utilized in sixteen lower extremity ulcers from eight patients following arterial vascular intervention. The bi-layered cell therapy\* was an extremely useful in healing this difficult lower extremity ulceration. The results suggest that bi-layered cell therapy\* is beneficial in healing lower extremity ulcerations following arterial vascular intervention.

**Product notation:** \* Apligraf<sup>®</sup> is a registered trademark of Novartis, Inc., East Hanover, NJ © 2004 Organogenesis, Inc., Canton, MA